サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1750820

中央研究所の市場規模、シェア、動向分析レポート：サービス別、最終用途別、地域別、セグメント予測、2025年～2030年

Central Lab Market Size, Share & Trends Analysis Report By Service (Genetic Services, Biomarker Services, Microbiology Services), By End-use (Pharmaceutical Companies, Biotechnology Companies), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 110 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.92円
中央研究所の市場規模、シェア、動向分析レポート：サービス別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年05月16日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中央研究所市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の中央研究所市場規模は2025年から2030年にかけてCAGR 6.56％を記録し、2030年には50億4,000万米ドルに達すると推定されています。

中央検査業務のアウトソーシングは市場成長を促進する重要な要因です。

中央研究所業務のアウトソーシングは臨床試験業界における増加動向であり、中央研究所にとって有利なビジネスチャンスが生まれると期待されています。治験責任医師やスポンサーは中央研究所業務の約80％を外注しており、エンドツーエンドの統合サービスを提供するラボを好んでいます。

研究開発への投資はここ数年急増しているが、これはパンデミック（世界的大流行）時に製薬業界への注目が高まったことに起因しています。パンデミックの3年目に入り、科学への投資はパイプラインを強化し、いくつかの臨床試験が開始されました。パンデミック期間中、インターベンショナルスタディの活動は着実に拡大しました。製薬業界は、パンデミック中に進行中の臨床試験を管理するための新しい試験実施方法を開発しました。

パンデミックは新たな成長機会も生み出し、mRNAワクチンの開発やCOVID-19治療法の検討への注目が高まっています。しかし、臨床ラボに送られるサンプルには、サンプルの取り扱い、サプライチェーン、ロジスティクスが重要な役割を果たしています。これらのサンプルは高感度であり、温度管理を伴う迅速なロジスティクスを必要とし、それにより最も正確な結果を得るためにサンプルの安定性を維持する必要があります。

中小規模の中央検査機関の台頭は、世界の競合を激化させています。中小規模の中央研究所の存在は、アジア太平洋などの開発途上地域で非常に顕著です。さらに、新興経済諸国では臨床試験の実施コストが低いため、これらの地域に存在する中央検査機関の選択が容易になっています。これは、物流コストが低く、臨床試験実施場所の近くに存在するためです。

中央研究所市場レポートハイライト

  • 遺伝子サービス分野は、臨床試験における遺伝子解析の重要性の高まりにより、予測期間中に最も速いCAGRで成長すると予測されます。
  • 戦略的買収は市場力学の変化に影響を与える要因の一つです。例えば、世界展開の強化や新規事業分野への参入を目的に、中堅・大企業が買収を行う。
  • 最終用途別では、製薬会社が2024年に44.78％の最大市場シェアを占めました。
  • 北米は2024年に40.82％のシェアで世界市場を独占しました。糖尿病やがんなどの疾患領域における個別化ヘルスケアに関連する臨床試験で遺伝子検査のニーズが高まっているためです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場展望
  • 市場力学
  • 市場促進要因
    • 臨床試験への研究開発投資の増加
    • 新薬の需要の高まり
    • 中央研究所業務のアウトソーシング
    • 医薬品調査コストの削減
  • 市場抑制要因分析
    • 物流とサンプル処理
  • ビジネス環境分析
    • SWOT分析;要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
    • COVID-19の影響分析

第4章 中央研究所市場：サービス別推定・動向分析

  • 中央研究所市場：サービス別変動分析
  • 遺伝子サービス
    • 遺伝子サービス中央研究所市場、2018年～2030年
  • バイオマーカーサービス
    • バイオマーカーサービス中央研究所市場、2018年～2030年
  • 微生物学サービス
    • 微生物学サービス中央研究所市場、2018年～2030年
  • 解剖病理学/組織学
    • 解剖病理学/組織学中央研究所市場、2018年～2030年
  • 検体管理と保管
    • 検体管理と保管中央研究室市場、2018年～2030年
  • 特殊化学サービス
    • 特殊化学サービス中央研究所市場、2018年～2030年
  • その他
    • その他中央研究所市場、2018年～2030年

第5章 中央研究所市場：最終用途別の推定・動向分析

  • 中央研究所市場：最終用途変動分析
  • 製薬会社
    • 製薬会社市場、2018年～2030年
  • バイオテクノロジー企業
    • バイオテクノロジー企業市場、2018年～2030年
  • 学術調査機関
    • 学術調査機関市場、2018年～2030年

第6章 中央研究所市場：地域別推定・動向分析

  • 中央研究所市場シェア：地域別、2023年および2030年
  • 北米
    • 北米の中央研究所市場、2018年～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州の中央研究所市場、2018年～2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • アジア太平洋地域の中央研究所市場、2018年～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカの中央研究所市場、2018年～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカの中央研究所市場、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参入企業の概要
  • 財務実績
  • 参入企業
    • マーケットリーダー
    • 中央研究所の市場シェア分析、2023年
    • 企業プロファイル
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 3 Global Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 4 Global Central Lab Market, by Region, 2018 - 2030 (USD Million)
  • Table 5 North America Central Lab Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 7 North America Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 8 U.S. Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 9 U.S. Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 Canada Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 11 Canada Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 12 Mexico Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 13 Mexico Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 14 Europe Central Lab Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 16 Europe Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Germany Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 18 Germany Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 UK Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 20 UK Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 21 France Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 22 France Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Italy Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 24 Italy Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Spain Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 26 Spain Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 27 Denmark Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 28 Denmark Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Sweden Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 30 Sweden Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 31 Norway Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 32 Norway Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Central Lab Market, by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 36 China Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 37 China Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Japan Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 39 Japan Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 40 India Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 41 India Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 42 South Korea Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 43 South Korea Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Australia Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 45 Australia Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 46 Thailand Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 47 Thailand Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Latin America Central Lab Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Latin America Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 50 Latin America Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 Brazil Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 52 Brazil Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 53 Argentina Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 54 Argentina Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 South Africa Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 58 South Africa Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 UAE Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 62 UAE Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 Kuwait Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Central Lab Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Central Lab Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Central Lab Market: Service Movement Analysis
  • Fig. 15 Global Central Lab Market, by Genetic Services, 2018 - 2030 (USD Million)
  • Fig. 16 Global Central Lab Market, by Biomarker Services, 2018 - 2030 (USD Million)
  • Fig. 17 Global Central Lab Market, by Anatomic Pathology/Histology, 2018 - 2030 (USD Million)
  • Fig. 18 Global Central Lab Market, by Specimen Management & Storage, 2018 - 2030 (USD Million)
  • Fig. 19 Global Central Lab Market, by Special Chemistry Services, 2018 - 2030 (USD Million)
  • Fig. 20 Global Central Lab Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 21 Global Central Lab Market: End Use Movement Analysis
  • Fig. 22 Global Central Lab Market, by Pharmaceutical Companies 2018 - 2030 (USD Million)
  • Fig. 23 Global Central Lab Market, by Biotechnology Companies 2018 - 2030 (USD Million)
  • Fig. 24 Global Central Lab Market, by Academic & Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 25 Regional Marketplace: Key Takeaways
  • Fig. 26 Regional Outlook, 2023 & 2030
  • Fig. 27 Global Central Lab Market: Region Movement Analysis
  • Fig. 28 North America Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 32 Europe Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 34 UK Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 35 France Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 36 Italy Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 37 Spain Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 38 Denmark Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 39 Sweden Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 40 Norway Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 42 Japan Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 43 China Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 44 India Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 45 Australia Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 48 Latin America Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 49 Brazil Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait Central Lab Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-962-2

Central Lab Market Growth & Trends:

The global central lab market size is estimated to reach USD 5.04 billion by 2030, registering a CAGR of 6.56% from 2025 to 2030, according to a new report by Grand View Research, Inc. The outsourcing of central lab work is a significant factor driving the market growth.

Outsourcing central lab work is a rising trend in the clinical trial industry, which is expected to create lucrative business opportunities for central labs. The investigators and sponsors outsource ~80% of the central lab work and prefer the labs that provide end-to-end integrated services.

Investment in R&D has witnessed a surge in past years, which can be attributed to the enhanced focus on the pharmaceutical industry during the pandemic. As we enter the third year of the pandemic, investment in science has enhanced the pipeline and several clinical trials have been initiated. Over the pandemic, activity in interventional studies grew steadily. The pharmaceutical industry developed a new way of conducting trials for the management of ongoing clinical trials during the pandemic.

The pandemic has also created new growth opportunities, with an increasing focus on mRNA vaccine development and investigations for several COVID-19 treatment options. However, sample handling, supply chain, and logistics play a significant role in the sample sent to clinical labs. These samples are highly sensitive and require fast logistics with temperature control, thereby maintaining sample stability to get the most accurate results.

The rise of small- and medium-scale central laboratories is intensifying the competition globally. The presence of small- and medium-scale central labs is highly prominent in developing regions such as the Asia Pacific. These laboratories are becoming critical in the management of clinical trials globally owing to the availability of central laboratory services at 20%-35% lower prices, when compared to Europe and the U.S. Furthermore, the lower cost of conducting clinical trials in the developing economies facilitates the selection of central laboratories present in these regions, which can be attributed to lower logistic costs and presence near the trial location.

Central Lab Market Report Highlights:

  • The genetic services segment is anticipated to grow at the fastest CAGR over the forecast period, owing to the increasing significance of genetic analysis in clinical studies.
  • Strategic acquisitions are one of the factors influencing the changing dynamics of the market. For instance, players are acquired by medium and large-scale enterprises for enhancing their global reach and entering new business segments.
  • By end-use, the pharmaceutical companies held the largest market share of 44.78% in 2024, attributable to an increasing number of interventional studies and investment into research.
  • North America dominated the global market in 2024 with a share of 40.82%, the increasing need for genetic testing in clinical trials related to personalized healthcare in disease areas, such as diabetes & cancers.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising R&D investment in clinical trial
    • 3.4.2. Escalating demand for novel drugs
    • 3.4.3. Outsourcing of central lab work
    • 3.4.4. Reducing the cost of drug research
  • 3.5. Market Restraint Analysis
    • 3.5.1. Logistics and sample handling
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Central Labs Market: Service Estimates & Trend Analysis

  • 4.1. Central Lab Market: Service Movement Analysis
  • 4.2. Genetic Services
    • 4.2.1. Genetic Services Central Lab Market, 2018 - 2030 (USD Million)
  • 4.3. Biomarker Services
    • 4.3.1. Biomarker Services Central Lab Market, 2018 - 2030 (USD Million)
  • 4.4. Microbiology Services
    • 4.4.1. Microbiology Services Central Lab Market, 2018 - 2030 (USD Million)
  • 4.5. Anatomic Pathology/Histology
    • 4.5.1. Anatomic Pathology/Histology Central Lab Market, 2018 - 2030 (USD Million)
  • 4.6. Specimen Management and Storage
    • 4.6.1. Specimen Management and Storage Central Lab Market, 2018 - 2030 (USD Million)
  • 4.7. Special Chemistry Services
    • 4.7.1. Special Chemistry Services Central Lab Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Central Lab Market, 2018 - 2030 (USD Million)

Chapter 5. Central Labs Market: End Use Estimates & Trend Analysis

  • 5.1. Central Lab Market: End-Use Movement Analysis
  • 5.2. Pharmaceutical Companies
    • 5.2.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 5.3. Biotechnology Companies
    • 5.3.1. Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 5.4. Academic and Research Institutes
    • 5.4.1. Academic and Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 6. Central Lab Market: Regional Estimates & Trend Analysis

  • 6.1. Central Lab Market Share By Region, 2023 & 2030
  • 6.2. North America
    • 6.2.1. North America Central lab market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Competitive Scenario
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Reimbursement Scenario
      • 6.2.2.5. U.S. Central lab market, 2018 - 2030 (USD MILLION)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Reimbursement Scenario
      • 6.2.3.5. Canada Central lab market, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Competitive Scenario
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Reimbursement Scenario
      • 6.2.4.5. Mexico Central lab market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Central lab market, 2018 - 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Reimbursement Scenario
      • 6.3.2.5. Germany Central lab market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Reimbursement Scenario
      • 6.3.3.5. UK Central lab market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Reimbursement Scenario
      • 6.3.4.5. France Central lab market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Reimbursement Scenario
      • 6.3.5.5. Italy Central lab market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Reimbursement Scenario
      • 6.3.6.5. Spain Central lab market, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Reimbursement Scenario
      • 6.3.7.5. Denmark Central lab market, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Reimbursement Scenario
      • 6.3.8.5. Sweden Central lab market, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Reimbursement Scenario
      • 6.3.9.5. Norway Central lab market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Central lab market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Scenario
      • 6.4.2.5. Japan Central lab market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Scenario
      • 6.4.3.5. China Central lab market, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. Reimbursement Scenario
      • 6.4.4.6. India Central lab market, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Reimbursement Scenario
      • 6.4.5.5. South Korea Central lab market, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Reimbursement Scenario
      • 6.4.6.5. Australia Central lab market, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Reimbursement Scenario
      • 6.4.7.5. Thailand Central lab market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Central lab market, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Scenario
      • 6.5.2.5. Brazil Central lab market, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Scenario
      • 6.5.3.5. Argentina Central lab market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Central lab market, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Scenario
      • 6.6.2.5. South Africa Central lab market, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Scenario
      • 6.6.3.5. Saudi Arabia Central lab market, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Scenario
      • 6.6.4.5. UAE Central lab market, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Scenario
      • 6.6.5.5. Kuwait Central lab market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant's overview
  • 7.2. Financial performance
  • 7.3. Participant categorization
    • 7.3.1. Market Leaders
    • 7.3.2. Central Lab Market Share Analysis, 2023
    • 7.3.3. Company Profiles
      • 7.3.3.1. ACM Global Laboratories
        • 7.3.3.1.1. Company Overview
        • 7.3.3.1.2. Financial Performance
        • 7.3.3.1.3. Product Benchmarking
        • 7.3.3.1.4. Strategic Initiatives
      • 7.3.3.2. LabConnect
        • 7.3.3.2.1. Company Overview
        • 7.3.3.2.2. Financial Performance
        • 7.3.3.2.3. Product Benchmarking
        • 7.3.3.2.4. Strategic Initiatives
      • 7.3.3.3. Cerba Research
        • 7.3.3.3.1. Company Overview
        • 7.3.3.3.2. Financial Performance
        • 7.3.3.3.3. Product Benchmarking
        • 7.3.3.3.4. Strategic Initiatives
      • 7.3.3.4. Eurofins Scientific
        • 7.3.3.4.1. Company Overview
        • 7.3.3.4.2. Financial Performance
        • 7.3.3.4.3. Product Benchmarking
        • 7.3.3.4.4. Strategic Initiatives
      • 7.3.3.5. Versiti (Cenetron)
        • 7.3.3.5.1. Company Overview
        • 7.3.3.5.2. Financial Performance
        • 7.3.3.5.3. Product Benchmarking
        • 7.3.3.5.4. Strategic Initiatives
      • 7.3.3.6. Medicover Integrated Clinical Services (MICS) (Synevo Central Labs)
        • 7.3.3.6.1. Company Overview
        • 7.3.3.6.2. Financial Performance
        • 7.3.3.6.3. Product Benchmarking
        • 7.3.3.6.4. Strategic Initiatives
      • 7.3.3.7. A.P. Moller Holding A/S (Unilabs)
        • 7.3.3.7.1. Company Overview
        • 7.3.3.7.2. Financial Performance
        • 7.3.3.7.3. Product Benchmarking
        • 7.3.3.7.4. Strategic Initiatives
      • 7.3.3.8. Ampersand Capital Partners (Pacific Biomarkers)
        • 7.3.3.8.1. Company Overview
        • 7.3.3.8.2. Financial Performance
        • 7.3.3.8.3. Product Benchmarking
        • 7.3.3.8.4. Strategic Initiatives
      • 7.3.3.9. Lambda Therapeutic Research Ltd
        • 7.3.3.9.1. Company Overview
        • 7.3.3.9.2. Financial Performance
        • 7.3.3.9.3. Product Benchmarking
        • 7.3.3.9.4. Strategic Initiatives
      • 7.3.3.10. CIRION BioPharma Research Inc.
        • 7.3.3.10.1. Company Overview
        • 7.3.3.10.2. Financial Performance
        • 7.3.3.10.3. Product Benchmarking
        • 7.3.3.10.4. Strategic Initiatives